C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home Markets Loading…
AKAN Equity

AKAN

OTCMKTS · AKAN

$3.86
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 3/5
35/100 composite
Fundamentals24
Regulatory49
Market40
Editorial30
Composite · trailing 12 months

Akanda Corp, under the ticker AKAN, receives a Neutral rating within the current framework. The composite score of 35.1 and a conviction of 3 out of 5 align the stock with its respective rating band. This rating reflects a balance among the four pillar categories, with regulatory factors taking the forefront, contributing most significantly, while editorial input trails. Market conditions currently provide minimal support due to an absence of reliable pricing information, and fundamentals reflect the company's constrained financial state, evident by pedestrian scores in factors like cash runway.

Analyzing the core data, Akanda's revenue growth year-over-year demonstrates a commendable upward trajectory, evidencing resilience despite stretched financial conditions. However, substantial challenges lie in negative gross and operating margins, which undeniably hinder profitability. The lack of net income and a notable EBITDA deficit compound concerns of fiscal sustainability, calling attention to the company's high cash burn ratio against modest market capitalization. With regulatory filings providing scant indication of future developments, adherence to timelines remains crucial in guiding future evaluations.

Regulatory factors serve as the primary catalyst in Akanda's potential fortification, where compliance and enforcement metrics showcase a strong jurisdictional foundation within the United States. Monitoring the regulatory landscape for any shifts in posture or new enforcement mechanisms will be critical for Akanda. This ongoing vigilance may deliver an important signal for future strategic adjustments should regulatory dynamics evolve, thus necessitating close observation for any subsequent assessments.

Scored: 2026-08-25Valid through: 2026-10-09Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
Corporate DetailsCompany profile
Headquarters
1A, 1B LEAROYD ROAD, NEW ROMNEY, X0, TN28 8XU
Phone
442034889514
Auditor
with our independent registered public accounting firm
SEC CIK
1888014
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$5.4M
Enterprise value
$19.1M
Price to book
2.21
Price to sales
20.83
EV / EBITDA
-0.80
Revenue (TTM)
$258K
Gross profit (TTM)
$-156K
EBITDA
$-4.7M
Operating margin
-1353.3%
Profit margin
0.0%
Rev growth YoY
21.9%
Return on equity
-60.9%
Return on assets
-44.1%
EPS (TTM)
$-15065.55
Shares outstanding
0.5M
Insider ownership
0.6%
Institutional ownership
1.9%
Beta
14.16
GICS sector
Healthcare
GICS industry
Drug Manufacturers - Specialty & Generic
Filings & DisclosuresPrimary sources
Annual report
Latest 10-K
Filing portal
SEC EDGAR
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for AKAN (AKAN)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for AKAN (AKAN), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for AKAN are maintained by Cannabis Investor News and refreshed throughout the trading day.